BGM Group Ltd.
corporate_fare Company Profile
BGM Group Ltd. (NASDAQ:BGM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for BGM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-28, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for BGM spans 6-K, 20-F.
Recent high-impact activity:
- BGM Group Confirms Highly Dilutive Private Placement, Reports Mixed Q1 2026 Financials
- BGM Group Calls New EGM After Cayman Regulator Rejects Prior Reverse Split Delegation
- BGM Group Chairman and Co-CEO Steps Down; Father Assumes Chair, New Co-CEO Appointed
- BGM Group 20-F Discloses $19.9M Loss, Material Weakness, Nasdaq Bid Price Deficiency, and a $12M Dilutive Placement
- Shareholders to Vote on Reverse Stock Split and Capital Reorganization
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 7,393 shares in BGM as of the October 30, 2026 settlement, a 10.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 46.0% of BGM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BGM, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.
Highly Dilutive Private Placement Confirmed · Revenue and Gross Profit Growth
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BGM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.